Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2022-04-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司2021年度独董述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2021年度独立董事述职报告" which translates to "2021 Annual Independent Directors' Work Report". It details the independent directors' qualifications, attendance at board and committee meetings, opinions on key matters such as related party transactions, use of raised funds, accounting policy changes, and overall evaluation of their duties during the year 2021. The content is a detailed report on the independent directors' activities and opinions for the fiscal year, which is a form of management or board report rather than a full annual report or audit report. It is not a simple announcement or certification but a substantive report on governance and oversight activities by independent directors. Therefore, the most appropriate classification is Board/Management Information (MANG).
2022-04-29 Chinese
奥锐特药业股份有限公司对外担保制度（2022年修订）
Governance Information Classification · 95% confidence The document is titled '对外担保制度' which translates to 'External Guarantee System' and details the internal control policies, procedures, risk management, approval processes, and disclosure requirements related to the company's external guarantees. It references relevant laws and company articles of association, and outlines responsibilities and penalties for violations. There is no financial data, earnings information, or report publication mentioned. The document is a governance or internal control policy document rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length is sufficient to be a full policy document, not a brief announcement or certification.
2022-04-29 Chinese
奥锐特药业股份有限公司信息披露管理制度（2022年修订）
Governance Information Classification · 95% confidence The document is titled '奥锐特药业股份有限公司 信息披露管理制度' which translates to 'Aruite Pharmaceutical Co., Ltd. Information Disclosure Management System'. It is a detailed internal policy document outlining the principles, responsibilities, procedures, and legal framework for information disclosure by the company. It references various types of reports such as annual reports, interim reports, and temporary reports, but it does not itself contain any financial data, results, or actual report content. Instead, it sets out the rules and governance for how such disclosures should be managed and conducted. It is a governance and compliance document related to disclosure practices rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length is substantial and it is not a mere announcement or certification, so it is not RPA or RNS. Hence, the classification is CGR with high confidence.
2022-04-29 Chinese
奥锐特药业股份有限公司第二届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 2nd Board of Directors of 奥锐特药业股份有限公司 (Aoruite Pharmaceutical Co., Ltd.) held on April 28, 2022. It includes voting results on various agenda items such as the 2021 annual board work report, general manager's report, independent directors' reports, audit committee reports, 2021 annual report and financial statements, profit distribution plan, internal control evaluation, appointment of auditors, and other governance and financing matters. The document repeatedly states that these resolutions will be submitted to the 2021 annual shareholders' meeting for approval. It also references disclosures on the Shanghai Stock Exchange website and various newspapers. The document is not the annual report itself but a formal announcement of board meeting decisions and resolutions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is 3815 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the correct classification is MANG with high confidence.
2022-04-29 Chinese
奥锐特药业股份有限公司2022年第一季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled '2022 年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2022. The report explicitly states it is unaudited and includes comprehensive financial metrics and analysis for the quarter. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is over 12,000 characters, indicating it is the full report, not just an announcement or summary. Therefore, the correct classification is IR with high confidence. Q1 2022
2022-04-29 Chinese
奥锐特药业股份有限公司2021年年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2021 Annual General Meeting (AGM) of 奥锐特药业股份有限公司, including the date, voting methods, agenda items, and procedural details. It does not contain the actual annual report, financial statements, or voting results, but rather the announcement and instructions for the AGM. The document length is 4120 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2022-04-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.